ClearPoint Neuro, Inc. (CLPT)

NASDAQ: CLPT · Real-Time Price · USD
16.72
-0.73 (-4.18%)
At close: Feb 21, 2025, 4:00 PM
16.51
-0.21 (-1.26%)
After-hours: Feb 21, 2025, 4:02 PM EST
-4.18%
Market Cap 461.22M
Revenue (ttm) 30.43M
Net Income (ttm) -18.15M
Shares Out 27.58M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 190,199
Open 17.45
Previous Close 17.45
Day's Range 16.67 - 17.45
52-Week Range 5.11 - 19.22
Beta 1.03
Analysts Strong Buy
Price Target 19.67 (+17.64%)
Earnings Date Feb 26, 2025

About CLPT

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; li... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1998
Employees 107
Stock Exchange NASDAQ
Ticker Symbol CLPT
Full Company Profile

Financial Performance

In 2023, ClearPoint Neuro's revenue was $23.96 million, an increase of 16.56% compared to the previous year's $20.55 million. Losses were -$22.09 million, 34.4% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CLPT stock is "Strong Buy." The 12-month stock price forecast is $19.67, which is an increase of 17.64% from the latest price.

Price Target
$19.67
(17.64% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025

SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

7 days ago - Accesswire

ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula

SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

9 days ago - Accesswire

ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati...

25 days ago - Accesswire

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the...

3 months ago - Accesswire

ClearPoint Neuro: Near-Term Volatility Is No Concern

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near ...

3 months ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Fi...

3 months ago - Seeking Alpha

ClearPoint Neuro Reports Third Quarter 2024 Results

Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a glob...

3 months ago - Accesswire

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CL...

4 months ago - Accesswire

ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

4 months ago - GlobeNewsWire

ClearPoint Neuro Announces Early Repayment of $10 Million Note

ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics

6 months ago - GlobeNewsWire

ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade)

ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser th...

6 months ago - Seeking Alpha

ClearPoint Neuro: My Favorite Growth Stock

ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat b...

7 months ago - Seeking Alpha

ClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Tak...

7 months ago - Seeking Alpha

ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

7 months ago - GlobeNewsWire

ClearPoint Neuro: Solid Progress Still Not Reflected In The Share Price

ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of n...

8 months ago - Seeking Alpha

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

8 months ago - GlobeNewsWire

Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons

Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System SAN DIEGO , June 20, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc. ann...

8 months ago - PRNewsWire

ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

9 months ago - GlobeNewsWire

ClearPoint Neuro, Inc. (CLPT) Q1 2024 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Joe Burnett – Chief Executive Officer Danilo D'Alessandro – Chief Financial Officer C...

10 months ago - Seeking Alpha

ClearPoint Neuro: Macro-Induced Multiple Compression

ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates.

10 months ago - Seeking Alpha

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia

11 months ago - GlobeNewsWire

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

SOLANA BEACH, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

1 year ago - GlobeNewsWire

ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

1 year ago - GlobeNewsWire

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

1 year ago - GlobeNewsWire